MONTREAL, June 28th, 2023 – Replicor Inc. presented its latest clinical data on the compassionate use of REP 2139-Mg in HBV / HDV co-infection at the 2023 Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria (see here).
Dr. Christiane Stern (Hôpital Beaujon, Clichy, France) presented updated clinical data at the Hepatitis Delta International Network (HDIN) satellite meeting where she highlighted the very positive impact of REP 2139-Mg therapy both on the disease and quality of life for her patients with decompensated cirrhosis. These impacts included the rapid reversal of symptoms of severe liver dysfunction, simultaneous clearance of HDV RNA and HBsAg and the establishment of persistent recompensation of cirrhosis and control of HBV and HDV infection after removal of therapy, enabling patients to be taken off the waiting list for liver transplantation.
More detailed presentations on the compassionate use of REP 2139-Mg in decompensated cirrhosis (Dr. Christiane Stern) and on a larger cohort of patients being rescued after failure on previous bulevirtide therapy (Dr. Marc Bourlière, Hôpital Saint Joseph, Marseille, France) highlighted these positive effects in both groups of patients.
Dr. Vaillant commented, “REP 2139-Mg continues to provide unmatched breakthrough results in the most difficult to treat patients which cannot be achieved with other drugs even in patients with mild disease. The pioneering work on-going with REP 2139-Mg in patients with decompensated cirrhosis continues to provide clear evidence of the remarkable safety envelope of REP 2139-Mg. We look forward to presenting additional evolving data from our compassionate program worldwide in the future.”
These presentations can be accessed at http://replicor.com/conference-presentations/.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.